Catalyst Pharmaceuticals, Inc.
Investor Relations Department
355 Alhambra Circle
Suite 1250
Coral Gables, FL 33134
United States

Visit IR website
Sign-up for email alerts

| NASDAQ: CPRX [1] | |
|---|---|
| Last Trade: | 1.96 |
| Trade Time: | 2:15 PM ET 03/27/17 |
| Change: | 0.26 (15.294%) |
| Day Range | 1.63 - 1.98 |
| 52-Week Range | 0.51 - 1.81 |
| Volume | 2,865,479 |
| Market Cap. ($M) | 162.621 |
| Shares Out (M) | 82.970 |

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Catalyst Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder. Catalyst's lead candidate, amifampridine phosphate, for the treatment of LEMS has completed testing in a global, multi-center, double-blinded randomized pivotal Phase 3 trial resulting in positive top-line data. Catalyst has recently filed an NDA for this product seeking approval for its use as a treatment of LEMS and Congenital Myasthenic Syndromes (CMS). Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourette's disorder, and movement disorders associated with the treatment of Parkinson's Disease.

... (more)

## Stock Performance

## Press Releases [ View all ]

*03/15/17*
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update

*03/15/17*
Catalyst Pharmaceuticals Announces Positive Data from Investigator-Sponsored Trial of Firdapse® in treating MuSK Antibody Positive Myasthenia Gravis

*03/10/17*
Catalyst Pharmaceuticals to Present at the 29th Annual ROTH Conference

*03/09/17*
Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results Conference Call and Webcast on Thursday, March 16th, 2017

*02/27/17*
Catalyst Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases

## Events [ View all ]

There are no events to display at this time. Please check back later.

## Financials [ View all ]

*03/15/17*
Annual Report (10-K)

*04/29/16*
Definitive Proxy Statement

*11/09/16*
Quarterly Report (10-Q)

*08/09/16*
Quarterly Report (10-Q)

*05/10/16*
Quarterly Report (10-Q)

Nasdaq